LaFleur & Godfrey LLC Has $16.48 Million Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

LaFleur & Godfrey LLC decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 31,055 shares of the medical research company’s stock after selling 330 shares during the quarter. Thermo Fisher Scientific comprises about 2.5% of LaFleur & Godfrey LLC’s investment portfolio, making the stock its 9th largest holding. LaFleur & Godfrey LLC’s holdings in Thermo Fisher Scientific were worth $16,484,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Cornell Pochily Investment Advisors Inc. increased its position in Thermo Fisher Scientific by 2.0% in the 4th quarter. Cornell Pochily Investment Advisors Inc. now owns 6,335 shares of the medical research company’s stock valued at $3,363,000 after acquiring an additional 124 shares during the period. Planned Solutions Inc. bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth about $301,000. Jacobs & Co. CA boosted its holdings in shares of Thermo Fisher Scientific by 21.0% in the fourth quarter. Jacobs & Co. CA now owns 14,166 shares of the medical research company’s stock valued at $7,519,000 after acquiring an additional 2,460 shares in the last quarter. Sterling Investment Management LLC raised its holdings in Thermo Fisher Scientific by 35.2% during the fourth quarter. Sterling Investment Management LLC now owns 6,281 shares of the medical research company’s stock worth $3,334,000 after purchasing an additional 1,634 shares in the last quarter. Finally, IFG Advisory LLC bought a new position in Thermo Fisher Scientific during the 4th quarter valued at $220,000. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Stock Performance

NYSE:TMO traded down $0.22 during mid-day trading on Thursday, hitting $579.15. 338,541 shares of the company’s stock traded hands, compared to its average volume of 1,606,165. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82. The firm has a market capitalization of $220.84 billion, a price-to-earnings ratio of 37.50, a price-to-earnings-growth ratio of 2.39 and a beta of 0.80. The firm has a 50 day moving average of $564.32 and a two-hundred day moving average of $519.80. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, beating analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The business had revenue of $10.89 billion during the quarter, compared to analyst estimates of $10.73 billion. During the same quarter in the prior year, the business earned $5.40 earnings per share. The firm’s revenue for the quarter was down 4.9% on a year-over-year basis. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, April 15th. Investors of record on Friday, March 15th will be given a $0.39 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a yield of 0.27%. The ex-dividend date of this dividend is Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.10%.

Analysts Set New Price Targets

Several research firms have issued reports on TMO. Wolfe Research assumed coverage on shares of Thermo Fisher Scientific in a research report on Wednesday, December 13th. They issued an “outperform” rating and a $575.00 price target on the stock. Sanford C. Bernstein reissued a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Citigroup assumed coverage on shares of Thermo Fisher Scientific in a research report on Monday, March 18th. They issued a “neutral” rating and a $620.00 target price on the stock. Barclays lowered shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and raised their price objective for the stock from $475.00 to $555.00 in a research note on Wednesday, January 24th. Finally, HSBC started coverage on Thermo Fisher Scientific in a research report on Monday, December 18th. They issued a “buy” rating and a $610.00 target price for the company. Five analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $599.00.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, Director Debora L. Spar sold 164 shares of the stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the transaction, the director now directly owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the transaction, the chief executive officer now owns 49,155 shares in the company, valued at approximately $27,311,992.65. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Debora L. Spar sold 164 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the sale, the director now owns 1,207 shares in the company, valued at approximately $660,192.79. The disclosure for this sale can be found here. Insiders have sold 50,277 shares of company stock valued at $28,513,384 in the last 90 days. 0.32% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.